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ABSTRACT
Aim Tissue engineering is a rapidly expanding field with regard to 
the use of biomaterials and stem cells in the orthopedic surgery. 
Many experimental studies have been done to understand the 
best characteristics of cells, materials and laboratory methods for 
safe clinical applications. The aim of this study was to compare the 
ability of 2 different human demineralized bone matrices (dBMs), 
the one enriched and the other not enriched with hyaluronic 
acid, to stimulate in vitro the proliferation and the osteogenic 
differentiation of human adipose-derived stem cells (adsCs) 
seeded onto an osteoconductive scaffold.
Materials and Methods adsCs were isolated, by enzymatic 
digestion, from abdominal adipose tissue of 5 patients undergoing 
cosmetic lipoaspiration surgery. adsCs were then seeded onto a 3d 
scaffold in the presence of the two different osteoinductive matrices 
of human demineralized bone and evaluated for proliferation and 
osteogenic differentiation. The safety of the methods was verified 
using array-Comparative Genomic Hybridization (array-CGH). 
Results adsCs were able to differentiate in osteogenic sense. 
Both dBMs showed the ability to induce osteogenic differentiation 
of the cells. 
Conclusion array-CGH showed no changes at genome level, thus 
confirming the safety of materials and methods.
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inTRoduCTion
Bone regeneration is a multifactorial process in which 
osteoconduction, osteoinduction, and osteogenesis play 
a key role (1). Osteoconduction refers to 3D materials 
(scaffolds), which favour adhesion, migration and 
proliferation of the cells able to directly synthesize 
new bone (osteogenesis) (2). Osteoinductive factors, 
mainly bone morphogenetic proteins (BMPs), growth 
factors (GFs) and demineralized bone matrices (DBMs), 
guarantee the recruitment of osteoprogenitor cells and 
the differentiation of stem cells in osteoblasts. Autologous 
bone graft is considered the gold standard for bone repair 
and regeneration because of its osteogenic, osteoinductive, 
and osteoconductive properties related to the presence of 
cells from bone and bone marrow, proteins in the matrix, 
and a 3D structure that provides a viable scaffold for the 
growth of the surrounding bone (3, 4). However, the use 
of autologous bone graft presents several limits, mainly 
dependent on the low amount of harvested bone, increase 
in operative time, pain, infection, hematoma, and blood 
loss (5-11).
A recent approach able to stimulate the regeneration 
of fully functioning bone tissue is based on the use of 
mesenchymal stem cells (MSCs) derived from adipose 
tissue cultured on an osteoconductive scaffold in presence 
of DBMs (12, 13).
Ceramics, mainly hydroxyapatite (HA), are widely used 
as scaffolds due to their physical and chemical similarity 
to the mineralized cancellous bone which guarantees the 
osteoconductivity (14). HA has a 3D porous structure 
determined by a network of crystalline mineral delimiting 
numerous interconnected pores of various sizes. Pores 
smaller than 10 µm allow the movement of extracellular 
fluids, while the ones larger than 50 µm support the cells 
growth and proliferation (15-18).
Ceramics are considered an excellent vehicle for 
osteoinductive GFs and osteogenic cells, since they 
are biocompatible, not toxic, and they do not cause 
immunological responses (19).
DBMs are produced by removal of minerals from cadaver 
cortical bone and are considered allografts (20). They 
consist of collagen (mainly type I but also type IV and type 
X), non-collagenous proteins, a minimum percentage of 
Ca3(PO4)2 (1-6%), and importantly BMPs and GFs essential 
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for bone growth and regeneration. The use of DBMs 
has some advantages, such as absence of rejection and 
foreign body reaction because antigenic surface structure 
of bone is destroyed during demineralization. DBMs are 
commercially available in various forms, including wafers, 
modeling paste, adhesive strips, and injectable compounds. 
Moreover, they can be molded even intraoperatively, they 
are intraoperative washing resistant, and they allow rapid 
vascularization after application. Problems related to the 
use of DBMs consist in the potential transmissibility of 
viruses (which has never been reported). DBMs are very 
expensive and they have different repair capability among 
different batches of product, due to variability in the 
quality of donor bone (20).
Recently, the interest towards the use of human adipose-
derived stem cells (ADSCs) in bone repair and regeneration 
is increasing. ADSCs are isolated from the stromal-vascular 
fraction of adipose tissue obtained during abdominoplastic 
surgical procedures, or during subcutaneous liposuction 
(21). ADSCs share many properties with bone marrow stem 
cells (BMSCs), especially the same differentiation potential. 
Notably, ADSCs possess many advantages associated to 
the easy harvesting, security, abundance and higher yield 
(high number of cells available from a single patient) (22-
24). Moreover, ADSCs are easily cultivated and expandable 
in vitro and have greater resistance in culture compared to 
BMSCs. ADSCs fulfill the International Society for Cellular 
Therapy (ISCT) criteria as they are plastic-adherent, express 
CD73, CD90 and CD105, lack CD34 antigens, and have a tri-
lineage mesenchymal differentiation (25).
Many studies have shown possible stem cells involvement in 
the process of oncogenesis in which malignant cells have the 
ability to proliferate and divide indefinitely without control 
(26, 27). It has been hypothesized that some pathways for 
self-renewal, finely regulated in the healthy stem cells, are 
altered in neoplastic diseases (28-34). Therefore, array-
Comparative Genomic Hybridization (array-CGH) analysis 
was performed in order to evaluate the genetic stability of 
ADSCs-based cultures. Array-CGH is a new technique that 
allows to identify copy number imbalances (gain and loss) 
of genetic material which are the basis of many disorders 
and diseases including cancer. Infact, array-CGH has many 
advantages with respect to classic cytogenetic methods, 
mainly due to higher resolution, higher reproducibility, and 
rapid and precise mapping of the whole genome (35).
The aim of the study was to evaluate the ability of 2 DBMs 
(TBM® e DBX®) to stimulate in vitro the proliferation and 
the osteogenic differentiation of mesenchymal stem cells 
isolated from adipose tissue. The safety of the methods 
was also investigated by means of molecular genetic tests.
 
MATeRiAlS And MeThodS
Scaffold
Orthoss® Blocks 1x1x2 cm (Geistlich Pharma AG, 
Wolhusen, Switzerland) were used in this study. 
Orthoss® is a natural carbonated HA of bovine origin. 
It is a highly osteoconductive material because of its 
particular structure, very similar to human cancellous bone, 
with interconnected macropores (100-300 µm), micropores, 
and nanopores (10-20 µm), resulting in a higher inner 
surface and excellent hydrophilic property (36).
demineralized Bone Matrices (dBMs)
Accell TBM® (Integra LifeScience Corporation, Irvine, CA, 
USA) is composed of 100% lyophilized human DBM which 
contains a broad spectrum of natural GFs. It is obtained 
through the proprietary Accell® DBM processing and it 
is provided in a sheet or "wafer" format. Accell TBM® is 
sterilized by electron beam irradiation.
DBX® Putty (Synthes Inc., West Chester, PA, USA) is 
composed of DBM (93% by volume) in sodium hyaluronate 
(4%) and phosphate dibasic buffer. It consists of collagen and 
bone GFs (mainly TGF-β), responsible of the osteoinductive 
properties. DBX is completely replaced by new host bone 
after 4 to 6 months. DBX® is aseptically produced processing 
the tissues in ISO class 5 static certified clean rooms.
isolation and expansion of human AdSCs
Adipose tissue was collected from the abdominal region 
of healthy patients (age, 35–58 years) who underwent 
liposuction cosmetic procedures. All patients gave written 
consent. The lipoaspirate was washed with Phosphate 
Buffered Saline (PBS, EuroClone, Milan, Italy) and digested 
using a solution of 0.075% collagenase from Clostridium 
histolyticum type II (Sigma-Aldrich, St. Louis, MO, USA) in 
Hank's Balanced Salt Solution (HBSS, Lonza S.r.l., Milano, 
Italy), for 3 h at room temperature and in slow agitation. At 
the end of the digestion, the collagenase activity was blocked 
with an equal volume of complete DMEM (cDMEM). cDMEM 
consisted of Dulbecco’s modified Eagle’s medium (DMEM, 
Lonza, Italy) supplemented with 10% Fetal Bovine Serum 
(FBS, Bidachem S.p.A., Milano, Italy) and 1% Penicillin/
Streptomycin (P/S, EuroClone). After centrifugation for 4 
min at 1200 rpm, the pellet was washed in PBS and filtered 
with a 70 µM cell strainer (BD Biosciences, Mississauga, 
Ontario, Canada). The cell suspension was resuspended in 
cDMEM, transferred to a 25-cm2 tissue culture flask, then 
incubated at 37°C and 5% CO2 for 15 days. Culture medium 
was changed every 2 days (37).
Cell counting
The viable cells were counted using the trypan blue exclusion 
test (38). At the confluence point, ADSCs were detached 
from the flasks with a solution of 0.25% trypsin ad 0.02% 
EDTA (EuroClone). After the addition of cDMEM, the cells 
were centrifuged for 4 min at 1200 rpm. The pellet was 
resuspended in cDMEM, then, 20 µl of the suspension were 
added to 80 µl of trypan blue for each culture. Cell counting 
was done using a Burker’s chamber. 
Cell characterization 
The expression of stemness markers was evaluated by 
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immunofluorescence. The cells, seeded on a glass slide, 
were fixed for 10 min at room temperature with 4% 
paraformaldehyde in PBS, pH 7.4. The slides were treated 
with 1% Bovine Serum Albumin (BSA, Sigma-Aldrich) for 
30 min to block non-specific sites, and then incubated at 
37°C for 1 h with the following primary antibodies: anti-
human CD73 (Abcam, Cambridge, UK), anti-human CD90 
(Abcam), anti-human CD105 (Santa Cruz Biotechnology Inc., 
CA, USA), anti-human fibroblasts (FU) (Abcam), and anti-
human CD34-FITC (Macs, Miltenyi Biotec GmbH, Germany). 
Subsequently, a second incubation was done at 37°C for 1 h 
with secondary antibodies: goat anti-mouse IgG DyLight 488 
labeled (KPL, Gaithersburg, MD, USA) or goat anti-rabbit IgG 
(H+L), DyLight 549 labeled (KPL, Gaithersburg, MD, USA).
3d cell cultures 
Cells were seeded at a density of 106/cm2 on the 3D 
Orthoss®scaffold alone (control), with TBM® (Orthoss® 
+ TBM®) or with DBX® (Orthoss® + DBX®). Two different 
media were used: standard medium (cDMEM) or osteogenic 
differentiation medium (cDMEM supplemented with 0.1 
µM dexamethasone, 200 µM L-ascorbic acid, and 10 mM 
β-glycerol phosphate). All 3D cultures were incubated at 37°C 
and 5% CO2 for 28 days, changing the medium every 2 days. 
The cell cultures were prepared as represented in Figure 1.
MTT assay
The biocompatibility of the materials was assessed 
at day 28 verifying cell viability and proliferation by 
the MTT (3-4,5-dimethylthiazol-2YL-2,5-bromuro 
diphenyltetrazolium) assay (39). The test is based on 
the ability of functional mitochondria to oxidize the 
MTT solution, giving a blue-violet product. In detail, the 
supernatant was aspirated from the tissue culture plate 
and 1 mL of 0.5 mg/mL MTT solution in PBS was added. 
After 3 h of incubation, the supernatant was aspirated, each 
scaffold was transferred to a microtube and 0.5 mL of 10% 
dimethyl sulfoxide in isopropanol was added to extract the 
formazan in the samples for 30 min at 37°C. For each sample, 
absorbance values at 570 nm were recorded in duplicate 
on 200 µL aliquots deposited in microwell plates using a 
multilabel plate reader (Victor 3 Perkin Elmer, Milano, Italy).
Real-time PCR
Total RNA was extracted on day 28 using the TRIzol® 
Reagent (Invitrogen, Carsbad, CA, USA). The samples 
were quantified using the NanoDrop spectrophotometer 
(NanoDrop™ 1000, Thermo Scientific). For the first-strand 
cDNA synthesis, 500 ng of total RNA was reverse transcribed 
using M-MLV RT (Moloney Murine Leukemia Virus Reverse 
Transcriptase, Invitrogen) according to the manufacturer's 
protocol. Human primers were selected for each target 
gene with Primer 3 software. Real-time PCRs were carried 
out using the designed primers at a concentration of 300 
nM and FastStart SYBR Green Master (Roche Diagnostics, 
Mannheim, Germany) on a Rotor-Gene 3000 (Corbett 
Research, Sydney, Australia). Thermal cycling conditions 
were as follows: 15 min denaturation at 95°C; followed by 
40 cycles of 15 s denaturation at 95°C; annealing for 30 s at 
60°C; and 20 s elongation at 72°C. Values were normalized 
to the expression of the β-actin internal reference, 
whose abundance did not change under our experimental 
conditions. Experiments were performed with 3 different 
cell preparations and repeated at least 3 times.
array-CGh
In order to identify possible chromosomal aberrations, such 
as deletions, amplifications, and aneuploidy, array-CGH 
was performed using the Human Genome CGH Microarray 
(Agilent Technologies, Santa Clara, CA, USA) with a median 
probe spatial resolution of 44 Kb. array-CGH was performed 
following the manufacturer's protocol. Briefly, 1 µg of 
DNA from human ADSCs cultures (sample) and 1 µg of 
pooled sex-matched reference DNA (Promega, Madison, 
WI, USA) were digested with AluI and RsaI for 2 h at 37°C. 
After inactivation of the enzymes at 65°C for 20 min, each 
digested sample was labeled by random priming (Genomic 
DNA Enzymatic Labelling Kit, Agilent Technologies) for 
2 h using Cy5-dUTP for sample DNA and Cy3-dUTP for 
reference DNA. Labeled products were then column-purified 
(Microcon YM-30 filters, Millipore Corporation, Billerica, 
MA, USA). After probe denaturation and pre-annealing 
with Cot-1 DNA, hybridization was performed at 65˚C with 
rotation for 24 h. At the end of the incubation, slides were 
washed and analyzed using the Agilent scanner. Data and 
graphics elaboration was done using the CGH Analytics 
software (V3.1 Agilent Technologies).
Statistical analysis
Statistical analysis was performed using the software 
SPSS 20.0.0. The comparison between groups was 
done using the Mann-Withney-U test. A p<0.05 was 
considered significant (*).
ReSulTS
Cell isolation and characterization
Human ADSCs were isolated from lipoaspirate by an 
enzymatic digestion, then grown as monolayer for 15 
days in cDMEM at 37°C and 5% CO2. ADSCs showed 
FiG. 1 schematic representation of the prepared 3d cell cultures.
Orthoss®
Orthoss® + TMB®
Orthoss® + DBX®
ADSCs
standard medium
ADSCs
osteogenic differentiation medium
Orthoss®
Orthoss® + TMB®
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FiG. 2 Morphology of adsCs isolated and cultured at 37°C with 5% Co2 at 
passage three. Cells show a spindle or a triangle-like morphology (20X 
magnification).
FiG. 4 MTT assay of 3d adsCs cultures in standard medium (left) and 
osteogenic differentiation medium (right). after 28 days of culture, the cells 
show the same ability to proliferate in presence of both TBM® and dBX®.
FiG. 5 Gene expression of some osteoblast markers in adsCs cultured for 
28 days in standard medium. Gene expression levels are higher in adsCs 
seeded in orthoss® + TBM® (* = p<0.05) compared to adsCs seeded in 
orthoss® alone or orthoss® + dBX®.
a fibroblastic-like morphology when observed under 
phase contrast microscope (Fig. 2). In agreement with 
the ISCT25, ADSCs were phenotypically characterized 
by immunofluorescence at passage three. The cells were 
positive for anti-CD73, -CD90 and -CD105 antibodies, 
negative for anti-CD34 and anti-FU antibodies (Fig. 3).
Biocompatibility of the scaffolds
ADSCs were able to proliferate onto the scaffolds, both 
in standard medium and osteogenic differentiation 
medium, as demonstrated by the MTT assay performed 
28 days after cell seeding (Fig. 4). These results 
demonstrated that the scaffolds were biocompatible 
and not toxic for the cell growth. 
Real-time PCR
The gene expression level of some osteoblast markers was 
analyzed at day 28 by means of Real-time PCR in order to 
verify the osteogenic properties of the materials used in the 
present study. The expression of selected genes (osteopontin, 
osteonectin, osteocalcin, type I collagen) was evaluated in 
relation to the expression of the reference gene (β-actin). 
Cells seeded on Orthoss® alone were used as control. In 
presence of standard medium, we found a significantly 
higher expression of selected genes in ADSCs seeded with 
TBM® compared to control and ADSCs grown with DBX®. 
On the contrary, there was not a significant difference 
in gene expression in the populations seeded with DBX® 
and control (Fig. 5). Osteogenic differentiation of ADSCs 
was, instead, similar independently of the biomaterials 
used (Fig. 6). 
array-CGh 
In order to verify the safety of both materials and 
methods, we performed array-CGH analyses of all 
the 3D ADSCs cultures after 28 days from seeding. 
FiG. 3 a-e immunofluorescence 
stainings of stemness markers in 
adsCs at passage three. adsCs were 
positive (red) for (a) Cd73, (B) Cd90 
and (C) Cd105; negative for (d) Fu and
 (e) Cd34 markers. Cell nuclei (blue) 
were stained with Hoechst33342.
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No chromosomal aberrations were detected in the 
experimental sets, confirming the biosafety of the 
Orthoss® scaffold, of both the DBMs as well as of the 
cell culture method used. 
 
diSCuSSion
Bone regeneration is a complex and multifactorial process 
that mainly needs the presence of osteoconductive 
(3D scaffold), osteoinductive (BMPs, GFs, and DBM), 
and osteogenic (bone-forming cells) factors (1). These 
properties are typically found in autologous bone graft; 
however, the disadvantages associated to its harvesting 
limit its use. For this reason, an alternative approach has 
been extensively studied with the aim to obtain a fully 
functioning bone. This strategy is based on the ability of 
MSCs to proliferate, self-renew and differentiate. MSCs 
can be harvested from many tissues, among which 
adipose tissue represents an abundant and accessible 
source (40, 41). Indeed, ADSCs have similar ability to 
proliferate and differentiate of BMSCs, in particular 
in osteogenic sense (42). Moreover, ADSCs possess 
additional advantages compared to BMSCs, mostly 
related to the great availability and yield (22).
On the basis of these knowledges, in the present study 
we tested the ability of ADSCs to differentiate towards 
the osteogenic phenotype in vitro when seeded on a 3D 
scaffold in presence of osteogenic factors. 
ADSCs were isolated, by enzymatic digestion, from the 
lipoaspirate of 5 healthy patients undergoing abdominal 
cosmetic liposuction. After an incubation period of 15 
days, positivity to CD73, CD90, and CD105 stem cell 
markers was verified by immunofluorescence. Negativity 
to FU and CD44 was also assessed. Then, ADSCs were 
seeded on Orthoss®, an HA scaffold necessary for 3D 
cell culture (1). ADSCs were also 3D cultured in presence 
of 2 different DBMs: TBM®, entirely composed of 
FiG. 6 Gene expression of some osteoblast markers in adsCs cultured for 
28 days in osteogenic differentiation medium. Gene expression levels are 
similar in adsCs seeded in orthoss® + TBM® (* = p<0.05) compared to 
adsCs seeded in orthoss® alone or orthoss® + dBX®.
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demineralized bone matrix, and DBX®, adjuvanted with 
sodium hyaluronate, able to stimulate the osteogenic 
differentiation. 
In order to compare the osteoinductive ability of the 2 
DBMs, cells were cultured in cDMEM or in osteogenic 
differentiation medium for 28 days. At the end of 
this period, the biocompatibility of the scaffolds was 
tested with the MTT assay by comparing viability 
of the cells cultured with or without differentiation 
medium. Proliferation rates were higher, although not 
significant, in the group of cells cultured in standard 
medium compared to the ones treated with osteogenic 
factors. This result could be explained by a slower ability 
of the cells to differentiate in standard medium, where 
they maintain stemness characteristics and, therefore, a 
greater replicative capacity. 
Moreover, we observed a lower proliferation rate 
of ADSCs seeded on Orthoss® + DBX® compared to 
Orthoss® + TBM® and also to the group only cultured on 
Orthoss® (control group). On day 28, the osteoinductive 
capacity of DBMs were evaluated by measuring the 
gene expression levels of osteopontin, osteonectin, 
osteocalcin and type I collagen. Real-time PCR results 
revealed the expression of all the genes analyzed, thus 
confirming the mature osteogenic phenotype of the 
cells. In detail, the results showed a significantly greater 
gene expression level in cells cultured with Orthoss® + 
TBM® compared to the control and to the Orthoss® + 
DBX® groups. On the contrary, there was no difference 
between the control and the Orthoss® + DBX® groups. 
This would suggest a greater ability for TBM® to induce 
osteogenic differentiation in vitro.
ADSCs were able to differentiate in osteogenic sense 
also in the group seeded on Orthoss® alone. It has been 
demonstrated that Orthoss® not only has osteoconductive 
ability but also osteoinductive properties due to its 
porous structure that ensures to the cells a habitat 
extremely similar to that of native bone (43, 44). The 
main difference between TBM® and DBX® consists in the 
presence of hyaluronic acid in the second material. As 
this molecule is abundantly found in vivo in the dermis, 
we hypothesized that the lesser osteoinductive capacity 
of DBX® compared to TBM® may be due to an interaction 
of hyaluronic acid with its receptor (CD44), normally 
expressed by MSCs. This interaction could alter the 
normal process of MSCs osteoinduction interfering with 
the normal pathways of differentiation and promoting 
the activity of the peroxisome proliferator activated 
receptor γ (PPAR γ), factor required for the adipogenic 
differentiation (48). Finally, we evaluated the safety of 
the method used with array-CGH analysis. This test is 
particularly important for further clinical applications. 
array-CGH is preferentially used to test genetic 
alterations, index of neoplastic transformation, because 
of its higher resolution than other cytogenetic and 
molecular methods. The analysis was performed on the 
entire genome of all 3D cultures, after 28 days of in vitro 
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culture. Results showed no alterations at the genome 
level. These data strongly supported the safety of both 
biomaterials and stem cells cultured in vitro, according to 
the methods used in this study.
ConCluSion
Based on the results of this study, it can be concluded 
that human ADSCs are able to adhere, proliferate and 
differentiate in osteoblast-like cells, also in absence of 
osteogenic factors. This confirms the osteoinductive 
ability of both the DBMs used. Moreover, the absence of 
genetic alterations demonstrates the safety of materials 
and cultures and supports their potential clinical 
application for bone reconstruction. The use of in vitro 
cultured autologous ADSCs is, therefore, promising 
for the clinical treatment of bone defects of various 
dimensions reducing the problems related to the use of 
non-autologous material and to the availability of great 
amount of materials.
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